SOURCE: UV Flu Technologies, Inc.

UV Flu Technologies, Inc.

June 11, 2010 16:05 ET

UV Flu Technologies Successfully Targets Athletics Sector With Latest Sale and Product Shipment

CENTERVILLE, MA--(Marketwire - June 11, 2010) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the Company's master distributor, Puravair, Inc., has completed a sales agreement and begun shipping the patented airborne bacteria-killing ViraTech UV-400 air purifier to a major national specialty sporting and athletics equipment distributor.

The sale was entered into with Massachusetts-based New England Sports Sales ("NESSI"), a national distributor of hockey and related equipment to college and professional hockey teams across the USA and Canada. "This product is a must for every locker room," said Charles Gultieri, President of NESSI. "This could be one of the most important developments to college and professional sports in the last 20 years."

"Athletic locker rooms are a perfect environment for the growth of bacteria and other airborne agents which can cause sickness," said Jack Lennon, the President of UV Flu Technologies. "One of the most common forms of bacteria we see in athletic locker rooms is staphylococcus aureus (staph infections). The ViraTech UV-400 air purifier is proven to kill the bacteria at a 99% success rate. Hockey, football, and basketball are all sports where preventing illnesses of key players are an ongoing and major issue, and can represent a significant ongoing cost factor to manage. Given the ease of use and proven ability our product has shown in improving indoor air quality, we believe the UV-400 can aid in the reduction of negative performance due to unhealthy air quality by providing team members a healthier environment both before and after every game. This issue goes beyond individual franchises right up the ladder to potentially help entire leagues mitigate the added cost burdens due to untimely airborne bacteria-caused illnesses."

Mr. Lennon added, "Locker rooms in health clubs, gymnasiums, and country clubs, along with many other high traffic health facilities, have all had their share of problems due to the transmission of bacteria, or have experienced significant cost burdens as a result of reactive measures taken to prevent the spread of disease. The UV-400 is an FDA cleared medical device which kills over 99% of all airborne bacteria with every pass, and it can pass the air up to several times per hour, helping to keep athletes healthy and safe. It really is a must for every locker room, and the fact that there is no filter to clog up or change is a major plus."

Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD

UV Flu Technologies, Inc.
-----------------------------
John J. Lennon, President & CEO

Contact Information